arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Programme

Sunday 20 Mar

08:30

Welcome

Plenary: State of the art Surgey

09:00

Value of CRS and HIPEC

Prof. Dr. Ignace de Hingh, Catharina Hospital, the Netherlands

09:30

Rectal surgery anno 2022

Prof. Dr. Joep Knol, Belgium

Parallel Symposia 1-5

Symposium 1: Liver metastasis-induction chemotherapy

10:15

Growth patterns of livermetastasis

Peter Vermeulen, GZA Hospitals St.Augustinus Antwerp, Belgium

10:30

Is there an optimal systemic induction regimen in patients with potentially resectable livermetastases?

Dr. Josep Tabernero

10:45

Hepatic artery infusion pump chemotherapy- SUNSET OR SUNRISE

Dr. Michael D’Angelica, MSKCC, United States

Symposium 2: Prognostic value of histological features on disease recurrence

10:15

Value of tumor deposits on disease recurrence

10:30

Value of lymph node metasis on disease recurrence

10:45

Recurrence of disease from a biological perspective: CMS score/Immunoscore

Symposium 3: Peritoneal metastasis

10:15

pT4 definition and risk PM, signet cell carcinoma, PM and CRS/HIPEC

Petur Snaebjornsson, Antoni van Leeuwenhoek, the Netherlands

10:30

The role of Micro-Satellite and RAS/RAF mutational status as prognostic factors in colorectal peritoneal metastases

Antonio Sommariva, Italy

10:45

Imaging of peritoneal metastases.

Max Lahaye, Antoni van Leeuwenhoek, the Netherlands

Symposium 4: What is the ideal assesment of an early rectal cancer- case based discussion

10:15

Case 1

Prof. Gina Brown, Professor of Gastrointestinal Cancer Imaging

10:30

Case 2

Prof.dr. Yutaka Saito, National Cancer Center Hospital, Chief of Endoscopy Division

10:45

Discussion on a proposed assesment algorithm

Prof.dr. Yutaka Saito, National Cancer Center Hospital, Chief of Endoscopy Division

Symposium 5: Clinical applications of circulating tumor DNA

10:15

ctDNA as biomarker to detect minimal residual disease

Claus Andersen

10:30

ctDNA as biomarker to guide therapy selection

T.B.C.

10:45

ctDNA as biomarker for monitoring treatment response

Dr. Remond Fijneman

Parallel Symposia 6-10

Symposium 6: Oligometastatic disease

11:00

Sabr COMET Phase III trial

Dr. David Palma, London Health Sciences Centre, United Kingdom

11:15

Cairo V

Prof. dr. Kees Punt, UMC Utrecht, the Netherlands

11:30

LUNA

Yun Shin Chun, MD Anderson Cancer Center, Houston, United States

11:45

Selected Abstracts

Symposium 7: Adjuvant treatment of high risk Stage II CRC

11:00

Neoadjuvant chemotherapy for colon cancer

11:15

Who needs adjuvant chemotherapy for colon cancer

11:30

Follow-up after surgery of high risk CRCs-spreker Primrose

11:45

Selected Abstracts

Sympsium 8: Local treatment of liver metastasis

11:00

Liver transplantation for liver metastasis

11:15

Rectal cancer with resectable liver metastasis

11:30

How far can you go with liver resection

11:45

Selected Abstracts

Sympsium 9: Histological evaluation of T1 CRCs

11:00

Controversies in assssing T1 CRCs- case based discussion

Dr. Maurice Loughrey, MRCP FRCPath MD is a consultant gastrointestinal pathologist, Royal Victoria Hospital, Belfast

11:15

TBC

Miangela Lacle

11:30

TBC

11:45

Selected Abstracts

Sympsium 10: Organoids for therapy selection

11:00

Patient-derived organoids for forward and reverse translational cancer research

Nicola Valeri, Institute of Cancer Research, United Kingdom

11:15

Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

11:30

Selected abstracts

11:45

Selected Abstracts

Sponsored Lunch sessions

Plenary: Treatment of T1 CRCs

13:00

Real life Recognition of T1 CRCs

Dr. Maria Pellise, Hospital Clinic of Barcelona

13:15

state of the art of Local excision of T1 CRCs

Dr. Mathieu Pioche, CHU de Lyon

13:30

How to treat high risk colon T1 CRC

MDT discussion with panel

Parallel symposiums 11- 15

Symposium 11: New developments Palliative systemic therapy

14:15

Triple therapy for RAS-mutation

Jeanine Roodhart, UMC Utrecht, the Netherlands

14:30

HER2 remming

Takayuki Yoshino, National Cancer Center Hospital East, Japan

14:45

Herintroductie van EFGR remming (CHRONOS studie)

Alberto Bardelli, Candiolo Cancer Institute IRCCS, Italy

Symposium 12: Treatment of recurrent rectal cancer

14:15

Extensive surgery and IORT in recurrent rectal cancer

14:30

The role of neo-adjuvant treatment in locally recurrent rectal cancer

14:45

Radiotherapy and systemic therapy for recurrent rectal cancer

Symposium 13: Treatment of liver metastasis with radio-embolisation

14:15

Introduction to radioembolization

Dr. María Macarena Rodríguez Fraile, Clínica Universidad de Navarra, Spain

14:30

Clinical indications and outcomes

Dr. Jon Bell, The Christie NHS Foundation Trust, United Kingdom

14:45

Future prospects of radioembolization

Prof. Dr. Marnix Lam, UMC Utrecht, the Netherlands

Symposium 14: Optical diagnosis- Selection of cases for en bloc resections

14:15

When to perform en bloc resections (cut-offs)

Yara Backes, UMC Utrecht, The Netherlands

14:30

When to go for primary surgery (cut-offs)

Prof. Helmut Messmann, Augsburg Medical Centre, Germany

14:45

AI instead of optical diagnosis by the endoscopist

Yuichi Mori, Digestive Disease Center, Showa University Northern Yokohama Hospital

Symposium 15: Biology of metastasis

14:15

Chromosomal instability and the tumor microenvironment

14:30

Genetic diversity in CRC metastases

14:45

Selected abstracts

15:00

Break

Parallel symposium 16-19

Symposium 16: Predicting treatment response

15:15

Predictive Value for Loss of Chromosome 18q11.2-q12.1 in metastatic CRC under Bevacizumab treatment

Prof. Dr. Bauke Ylstra, Amsterdam UMC, the Netherlands

15:30

WGS reveals prior treatment effects

Dr. Saskia Wilting, Erasmus MC Rotterdam, the Netherlands

15:45

Personalized treatmen in the clinical setting - how to do it?

Prof. Dr. Eric Van Cutsem, UZ Leuven, Belgium

16:00

Selected Abstracts

Symposium 17: Organ preservation for early (T2-T3) rectal cancer

15:15

neoadjuvant radiotherapy for organ preservation

15:30

neoadjuvant chemoradiation for organ preservation

15:45

neoadjuvant systemic treatment for organ preservation

16:00

Selected Abstracts

Symposium 18:

TRIALS for T1 CRCs

15:15

What are the important endpoints

Rodrigo Perez

15:30

PROMS for T1 CRCs

Jurriaan Tuynman, Amsterdam UMC, the Netherlands

15:45

What is the optimal study design

T.B.C.

16:00

Selected Abstracts

Symposium 19

15:15

imaging CRC metastasis

15:30

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver

15:45

Selected abstracts

16:00

Selected abstracts

16:30

Break

Key note lecture

16:45

Local treatment of liver metastasis

Åsmund Avdem Fretland, Oslo Univeristy Hospital, Norway